Du måste aktivera javascript för att sverigesradio.se ska fungera korrekt och för att kunna lyssna på ljud. Har du problem med vår sajt så finns hjälp på https://kundo.se/org/sverigesradio/
Det brinner i en industrilokal med giftig rök som sprider sig österut mot Giraffens köpcentrum. Räddningsledaren uppmanar alla personer som befinner sig i området att bege sig därifrån. Ni som bor i området uppmanas att gå inomhus och stänga dörrar, fönster och ventilation. För mer information lyssna på Sveriges Radio P4 Kalmar.
(Publicerat idag kl 17.16)

New blood test improves prostate cancer screening

Published tisdag 10 november 2015 kl 12.15
"Important step towards general screening"
(2:36 min)
A study from Sweden's Karolinska Institutet shows a new test for prostate cancer is better at detecting aggressive forms of the disease. Photo: Dan Hermansson / TT.
A study from Sweden's Karolinska Institutet shows a new test for prostate cancer is better at detecting aggressive forms of the disease. Photo: Dan Hermansson / TT.

Swedish researchers have developed a new blood test for prostate cancer that they say is better at detecting aggressive forms of the disease than previous tests.

The researchers from Stockholm's Karolinska Institutet published their results in the scientific journal The Lancet Oncology and say the new test also reduces the number of false positives and unnecessary biopsies.

According to the study, which involved some 60,000 men from the Stockholm area, the number of biopsies was cut by a third, compared with what's common from the old screening test for prostate cancer. 

"That's considerably more than we had originally thought, so I'm incredibly happy," Henrik Grönberg, a professor at Karolinska Institutet and head researcher behind the new test, tells news agency TT. "It saves a lot of suffering and anxiety."

Prostate cancer is the second most common cancer among men worldwide. Health care professionals currently used what's called a PSA test to diagnose the cancer though the method is unable to distinguish between aggressive and benign cancers.

The new method, referred to as the STHLM3 test, analyzes a patient's blood sample by looking at a combination of six protein markers, over 200 genetic markers as well as clinical data, such as a patient's age and family history.

Our journalism is based on credibility and impartiality. Swedish Radio is independent and not affiliated to any political, religious, financial, public or private interests.
Har du frågor eller förslag gällande våra webbtjänster?

Kontakta gärna Sveriges Radios supportforum där vi besvarar dina frågor vardagar kl. 9-17.

Du hittar dina sparade avsnitt i menyn under "Min lista".